Indication hub
Heart Failure clinical trials — Miami
Amavita Research is the GCSA-certified Miami cardiovascular trial site: TAVR-pioneer senior PI, an in-house South Florida heart practice, and a dedicated cardiovascular ASC.
Amavita Research runs heart-failure protocols from one North Miami Beach research suite, with a dedicated cardiovascular ASC for device and interventional work. Public heart-failure studies on the homepage are listed below. Dr. Pedro Martinez-Clark is a principal investigator on this work. Dr. William W. O'Neill is the senior PI.
Public studies
- Phase 2EnrollingPfizer C4921003 — PF-07328948 in HFpEF
Sponsor: Pfizer
Phase 2 study of PF-07328948, an oral branched-chain ketoacid dehydrogenase (BCKD) kinase inhibitor, in adults with heart failure. The trial evaluates the metabolic pathway that branched-chain amino acid catabolism plays in cardiac function in HFpEF.
- Phase 3EnrollingHERMES — Ziltivekimab in Heart Failure
Sponsor: Novo Nordisk
A Phase 3 randomized, placebo-controlled trial evaluating ziltivekimab, a fully human monoclonal antibody targeting interleukin-6, in patients with heart failure and systemic inflammation. Amavita Research Services is an enrolling site, with Dr. Pedro Martinez-Clark as Principal Investigator.
- Phase 2BStart-upAnaCardio AC01 — Ghrelin Receptor Agonist in HFrEF
Sponsor: AnaCardio AB
Phase 2B study of AC01, an oral ghrelin receptor agonist, administered over 12 weeks in patients with chronic advanced heart failure with reduced ejection fraction (HFrEF). The trial is in site start-up.
- Phase 3EnrollingICONIC-HF — Ferric Derisomaltose in Iron-Deficiency Heart Failure
Sponsor: Pharmacosmos
Phase 3 trial of ferric derisomaltose (intravenous iron) versus no intravenous iron in iron-deficient subjects with symptomatic chronic heart failure. ICONIC-HF measures the impact of IV iron supplementation on HF outcomes.
- RegistryStart-upOPEN HF Registry — Impulse Dynamics
Sponsor: Impulse Dynamics
Cardiac contractility modulation (CCM) heart-failure registry. Amavita Research Services, LLC is a start-up site under a CTA executed 19 August 2026.
Investigators
- Dr. William W. O'Neill, MD, FACC — Senior Principal Investigator
- Dr. Pedro Martinez-Clark, MD, FACC — Principal Investigator
- Dr. Hans C. Rutzen-Lopez, MD — Cardiac Electrophysiology — Sub-Investigator
Why Amavita Research for heart failure
- In-house South Florida heart practice supplies heart-failure patient flow for screening.
- One current research suite at 100 NW 170 Street, North Miami Beach. Kendall is opening — it is not a current site.
- Dedicated cardiovascular ASC at 9408 SW 87th Ave Suite 303 for interventional and device protocols.
- IAOCR GCSA recertified May 2026 through February 2027. ICH-GCP E6(R3).
New-sponsor first-touch
Julio G. Martinez-Clark
CEO, Amavita Research Services, LLC
New-sponsor first-touch, CDA, and NDA. Julio signs CDAs. Dr. Pedro Martinez-Clark is a principal investigator only. After a study is awarded, Nereisy Alonso, Sr CRC, COO owns study operations: monitors and start-up logistics.
Contact Julio about a protocolLocations
Where this work happens
- One North Miami Beach research suite at 100 NW 170 Street. This is the current research site of record.
- Dedicated cardiovascular ASC at 9408 SW 87th Ave Suite 303.
- Kendall is opening — it is not a current site.